Proactive Investors - Faron Pharma (LON:FARN)’s latest results from the BEXMAB trial in aggressive myeloid leukaemias (a rare blood cancer) showed more promising results, according to broker Peel Hunt (LON:PEEL).
Responses were noted in the two groups where previous treatments had failed, with seven out of ten of these seeing a complete response/marrow response.
Peel Hunt added the treatment, bexmarilimab, presents a very promising approach to igniting immunity, allowing a patient’s immune system to overcome resistance from the ‘tumour microenvironment’ or to supplement/enhance existing immuno-oncology approaches.
Faron added that it is well positioned to advance to the Phase 2 part of the BEXMAB study and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing.
Peel Hunt has a target price of 417p.